The Prophylaxis of Tuberculosis According to TSPOT Results After Kidney Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

303 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-01

Study Completion Date

2023-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Organ transplant recipients are a high incidence group of tuberculosis infection, and the incidence rate is 7-27 times that of the general population. The prevention of postoperative tuberculosis infection is an important part of kidney transplant recipients postoperative follow-up. Taking reasonable tuberculosis prevention strategies for organ transplant recipients can better prevent the occurrence of postoperative tuberculosis and reduce the unreasonable use of anti-tuberculosis drugs. The previous screening methods for active tuberculosis mainly include sputum smear culture, tissue biopsy, tuberculin skin test, tuberculosis antibody, tuberculosis DNA, and chest imaging. However, there is still a lack of accurate and effective means for screening for latent tuberculosis infection. The tuberculosis interferon-γ release test has recently received more and more attention as a means of screening for potential tuberculosis infection. However, how to apply tuberculosis interferon-γ release test in clinical practice is still controversial. The investigators hope to explore the clinical application prospects and practical value of tuberculosis interferon-γ release test through this research.

According to the conclusion of the retrospective study, the investigators found that the recipients with negative TSPOT result maybe don't need follow the isoniazid treatment to prevent the development of tuberculosis even though participants have clinical risk factor of tuberculosis(include past tuberculosis history, the close contact with active tuberculosis patients, an area with a high incidence of tuberculosis, abnormal chest x ray performance ).

The investigators will divided the recipients with tuberculosis risk factors into three groups randomly. Of course, the invention require written informed consent. The first group with positive tuberculosis interferon gamma release assay (TSPOT) result will follow through with the treatment ,which is a daily dose of isoniazid for six months(300mg daily) after kidney transplant surgery. The second group with negative TSPOT result will not follow through the isoniazid treatment. The third group will follow through with the isoniazid treatment no matter their TSPOT results. The investigators will conduct a prospective clinical trial with the first aim of exploring the effectiveness of TSPOT results in kidney transplant recipients with clinical tuberculosis risk factors, and the second aim of exploring the benefit of the isoniazid treatment follow the TSPOT results rather than clinical risk factors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Isoniazid Prophylaxis Based on Risk Factors of Tuberculosis in Living Kidney Transplantation Recipients

NCT06512831

Kidney Transplantation Tuberculosis Isoniazid Toxicity

COMPLETED NA

Latent Tuberculosis Infection in Renal Transplant Recipients

NCT00682045

Renal Transplant

COMPLETED

Isoniazid (INH) Treatment Based on ELISPOT Assay

NCT01087190

Kidney Transplant Recipient

COMPLETED NA

The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in Patients With Kidney Transplantation: a Prospective Intervention Pilot Study

NCT05588492

Pulmonology

RECRUITING PHASE4

Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention

NCT02430259

Silicosis Tuberculosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Transplant Infection Tuberculosis Isoniazid Toxicity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Positive TSPOT results with clinical risk factors group

patients receive isoniazid 300mg once daily for six months after kidney transplant surgery form discharge

Group Type EXPERIMENTAL

Isoniazid

Intervention Type DRUG

prevent the development of tuberculosis

Negative TSPOT results with clinical risk factors group

patients receive no additional therapy

Group Type PLACEBO_COMPARATOR

without any additional anti-tuberculosis treatment

Intervention Type OTHER

reduce the number of Participants With Treatment-Related Adverse Events

Clinical risk factors group

patients receive isoniazid 300mg once daily for six months after kidney transplant surgery form discharge

Group Type EXPERIMENTAL

Isoniazid

Intervention Type DRUG

prevent the development of tuberculosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Isoniazid

prevent the development of tuberculosis

Intervention Type DRUG

without any additional anti-tuberculosis treatment

reduce the number of Participants With Treatment-Related Adverse Events

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. living-donor kidney transplantation;
2. eGFR level \> 45ml/min/1.73m2 at discharge;
3. 18\<Age \<65years;
4. receiving standard triad immunosuppressive regimen

Exclusion Criteria

1. alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2.5 or more of upper limit of normal
2. Combined with HBV/HCV/HIV/TB infection in the donor or recipient;
3. Malignancy history in the donor and recipient;
4. organ transplant history in the recipient.
5. The positive TSPOT result or past TB history in the donor

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No